These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35125303)

  • 1. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
    Grossmann NC; Pradere B; D'Andrea D; Schuettfort VM; Mori K; Rajwa P; Quhal F; Laukhtina E; Katayama S; Fankhauser CD; Xylinas E; Margulis V; Moschini M; Abufaraj M; Bandini M; Lonati C; Nyirady P; Karakiewicz PI; Fajkovic H; Shariat SF
    Clin Genitourin Cancer; 2022 Jun; 20(3):227-236. PubMed ID: 35125303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF
    BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    Lee Y; Kim YS; Hong B; Cho YM; Lee JL
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K
    Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
    Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
    Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Margulis V; Puligandla M; Trabulsi EJ; Plimack ER; Kessler ER; Matin SF; Godoy G; Alva A; Hahn NM; Carducci MA; Hoffman-Censits J;
    J Urol; 2020 Apr; 203(4):690-698. PubMed ID: 31702432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
    Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R
    BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
    Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma.
    Ghandour RA; Freifeld Y; Cheaib J; Singla N; Meng X; Kenigsberg A; Bagrodia A; Woldu S; Hoffman-Censits J; Enikeev D; Rapoport L; Petros FG; Raman JD; Pierorazio PM; Matin SF; Margulis V
    Urol Oncol; 2021 Nov; 39(11):788.e15-788.e21. PubMed ID: 34330655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
    Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
    Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
    Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
    Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
    Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
    Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
    Calleris G; Rouprêt M; Seisen T; Bendjeddou L; Chevallier T; Masson-Lecomte A; Thibault C; Neuzillet Y; Audenet F; Xylinas E; Houédé N
    World J Urol; 2023 Dec; 41(12):3413-3420. PubMed ID: 37698632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
    Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
    BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
    Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
    World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.